Shinji Nagahiro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shinji Nagahiro has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Hidetaka Koizumi
Department of Clinical Neuroscience, Institute of Health Biosciences, The University of Tokushima Graduate School Tokushima, Japan
1 shared publication - Masanori Nakagawa
North Medical Center, Kyoto Prefectural University of Medicine, Kyoto, Japan
1 shared publication - Ryoma Morigaki
Department of Neurosurgery, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan
1 shared publication - Ryuji Kaji
Tokushima University Graduate School of Medicine, Tokushima, Japan
1 shared publication - Satoshi Goto
Department of Clinical Neuroscience, Institute of Health Biosciences, Graduate School of Medicine, University of Tokushima, Tokushima, Japan
1 shared publication - Shinya Okita
Department of Motor Neuroscience and Neurotherapeutics, Graduate School of Medical Sciences, Institute of Health Biosciences, University of Tokushima Tokushima, Japan
1 shared publication
Latest Publications
- 1 June 2014
- Published by Elsevier in Applied Radiation and Isotopes
- Vol. 88, 28-31
Nine-year interval recurrence after treatment of boron neutron capture therapy in a patient with glioblastoma: A case report
- 1 June 2014
- Published by Elsevier in Applied Radiation and Isotopes
- Vol. 88, 28-31
Nine-year interval recurrence after treatment of boron neutron capture therapy in a patient with glioblastoma: A case report
- Open Access
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Cellular Neuroscience
- Vol. 7, 74
Response of striosomal opioid signaling to dopamine depletion in 6-hydroxydopamine-lesioned rat model of Parkinson's disease: a potential compensatory role
The opioid peptide receptors consist of three major subclasses, namely, μ, δ, and κ (MOR, DOR, and KOR, respectively). They are involved in the regulation of striatal dopamine functions, and increased opioid transmissions are thought to play a compensatory role in altered functions of the basal ganglia in Parkinson's disease (PD). In this study, we used an immunohistochemistry with tyramide signal amplification (TSA) protocols to determine the distributional patterns of opioid receptors in the striosome-matrix systems of the rat striatum. As a most striking feature of striatal opioid anatomy, MORs are highly enriched in the striosomes and subcallosal streak. We also found that DORs are localized in a mosaic pattern in the dorsal striatum (caudate-putamen), with heightened labeling for DOR in the striosomes relative to the matrix compartment. In the 6-hydroxydopamine-lesioned rat model of PD, lesions of the nigrostriatal pathways caused a significant reduction of striatal labeling for both the MOR and DOR in the striosomes, but not in the matrix compartment. Our results suggest that the activities of the striosome and matrix compartments are differentially regulated by the opioid signals involving the MORs and DORs, and that the striosomes may be more responsive to opioid peptides (e.g., enkephalin) than the matrix compartment. Based on a model in which the striosome compartment regulates the striatal activity, we propose a potent compensatory role of striosomal opioid signaling under the conditions of the striatal dopamine depletion that occurs in PD.
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Cellular Neuroscience
- Vol. 7, 74
Open AccessResponse of striosomal opioid signaling to dopamine depletion in 6-hydroxydopamine-lesioned rat model of Parkinson's disease: a potential compensatory role
The opioid peptide receptors consist of three major subclasses, namely, μ, δ, and κ (MOR, DOR, and KOR, respectively). They are involved in the regulation of striatal dopamine functions, and increased opioid transmissions are thought to play a compensatory role in altered functions of the basal ganglia in Parkinson's disease (PD). In this study, we used an immunohistochemistry with tyramide signal amplification (TSA) protocols to determine the distributional patterns of opioid receptors in the striosome-matrix systems of the rat striatum. As a most striking feature of striatal opioid anatomy, MORs are highly enriched in the striosomes and subcallosal streak. We also found that DORs are localized in a mosaic pattern in the dorsal striatum (caudate-putamen), with heightened labeling for DOR in the striosomes relative to the matrix compartment. In the 6-hydroxydopamine-lesioned rat model of PD, lesions of the nigrostriatal pathways caused a significant reduction of striatal labeling for both the MOR and DOR in the striosomes, but not in the matrix compartment. Our results suggest that the activities of the striosome and matrix compartments are differentially regulated by the opioid signals involving the MORs and DORs, and that the striosomes may be more responsive to opioid peptides (e.g., enkephalin) than the matrix compartment. Based on a model in which the striosome compartment regulates the striatal activity, we propose a potent compensatory role of striosomal opioid signaling under the conditions of the striatal dopamine depletion that occurs in PD.